Lithium Augmentation in Depressive Patients Not Responding
to Selective Serotonin Reuptake Inhibitors[1]

 

 Buy Article Permissions and Reprints

This communication reviews current literature on lithium augmentation in patients not responding to SSRIs, giving some recommendations at the end. A significant proportion of depressive patients do not respond to a first antidepressive treatment independently of the class of drugs used. During the last 10 years, there have been several case reports published about open and controlled studies on the use of lithium augmentation in patients who were non-responders to SSRIs, including citalopram, fluoxetine, paroxetine and sertraline. The main underlying hypothesis is a synergistic effect between SSRIs and lithium, which both act on serotonergic neurotransmission. The available studies vary considerably in methodology. There are insufficient results available to confirm a rapid improvement (within 24 - 48 h) after introduction of lithium, but most studies show substantial effects after 1 - 2 weeks, and some after 6 weeks. There is as yet no more clear evidence for a pharmacokinetic interaction between lithium and SSRIs with pharmacodynamic consequences. In conclusion, present evidence suggests that a lithium augmentation in depressive patients who do not respond to SSRIs may be an efficacious and generally well tolerated treatment, with a response rate of at least 50 % after a period lasting 1 - 2 weeks. However, special care is indicated when treating elderly patients, where the risk of adverse effects is higher.

1 This contribution was part of an oral presentation at the ECNP meeting in Vienna, 1997 (Baumann, P. Advantages and disadvantages of lithium augmentation. Eur. Neuropsychopharmacol. 7 (suppl. 2): the S82, 1997. [Abstract])

References

• 1 Adli M, Bschor T, Canata B, Döpfmer S, Bauer M. Lithium in der Behandlung der akuten Depression.  Fortschr Neurol Psychiat. 1998;  66 435-441
  PubMedGoogle Scholar
• 2 American Psychiatric Association . Practice guideline for major depressive disorder in adults.  Am J Psychiatry. 1993;  150 (Suppl 4)
  PubMedGoogle Scholar
• 3 Anderson I M. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.  Depression and Anxiety. 1998;  7 (Suppl. 1) 11-17
  CrossrefPubMedGoogle Scholar
• 4 Aronson R, Offman H J, Joffe R T, Naylor C D. Triiodthyronine augmentation in the treatment of refractory depression.  Arch Gen Psychiatry. 1996;  53 842-848
  CrossrefPubMedGoogle Scholar
• 5 Austin L S, Arana G W, Melvin J A. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.  J Clin Psychiatry. 1990;  51 344-345
  PubMedGoogle Scholar
• 6 Barak Y, Stein D, Levine J, Ring A, Hadjez J, Elizur A, Shoshani D. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly.  Hum Psychopharmacol. 1996;  11 463-467
  PubMedGoogle Scholar
• 7 Bauer M. The combined use of lithium and SSRIs.  J Serotonin Res. 1995;  2 69-76
  PubMedGoogle Scholar
• 8 Bauer M. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine.  J Clin Psychopharmacol. 1996;  16 130-134
  CrossrefPubMedGoogle Scholar
• 9 Bauer M, Hellweg R, Graf K J, Baumgartner A. Treatment of refractory depression with high dose thyroxine.  Neuropsychopharmacology. 1998;  18 444-455
  CrossrefPubMedGoogle Scholar
• 10 Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.  J Clin Psychopharmacol. 1999;  19 427-434
  CrossrefPubMedGoogle Scholar
• 11 Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle A, Müller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation tratment of unipolar major depression.  Am J Psychiatry. 2000;  157 1429-1435
  CrossrefPubMedGoogle Scholar
• 12 Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.  J Clin Psychopharmacol. 1996;  16 307-314
  CrossrefPubMedGoogle Scholar
• 13 Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs.  Int Clin Psychopharmacol. 1998a;  13 S35-S43
  PubMedGoogle Scholar
• 14 Blier P, Bergeron R. The use of pindolol to potentiate antidepressant medication.  J Clin Psychiatry. 1998;  59 16-23
  PubMedGoogle Scholar
• 15 Bodkin J A, Lasser R A, Wines J D, Gardner D M, Baldessarini R J. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.  J Clin Psychiatry. 1997;  58 137-145
  PubMedGoogle Scholar
• 16 Breuel H P, Müller-Oerlinghausen B, Nickelsen T, Heine P R. Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers.  Int J Clin Pharmacol Ther. 1995;  33 415-419
  PubMedGoogle Scholar
• 17 Byrne S E, Rothschild A J. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.  J Clin Psychiatry. 1998;  59 279-288
  PubMedGoogle Scholar
• 18 Camprubi M E, Puri B K. The treatment of refractory depression using paroxetine with lithium augmentation.  Prog Neuropsychopharmacol Biol Psychiat. 1995;  19 515-517
  CrossrefPubMedGoogle Scholar
• 19 De Angelis L. Lithium treatment and the geriatric population.  Int J Clin Pharmac Ther Toxicol. 1990;  28 394-398
  PubMedGoogle Scholar
• 20 De Montigny C, Grunberg F, Mayer A. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders.  Br J Psychiatry. 1981;  138 252-256
  PubMedGoogle Scholar
• 21 De Montigny C, Cournoyer G, Moriseett R. Lithium carbonate additionin tricyclic antidepressant-resistant unipolar depression.  Arch Gen Psychiatry. 1983;  40 1327-1334
  PubMedGoogle Scholar
• 22 De Montigny C. Lithium addition in treatment-resistant depression.  Int Clin Psychopharmacol. 1994;  9 31-35
  PubMedGoogle Scholar
• 23 Delgado P L, Price L H, Charney D S, Heninger G R. Efficacy of fluvoxamine in treatment-refractory depression.  J Affect Disord. 1988;  15 55-60
  CrossrefPubMedGoogle Scholar
• 24 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 51-58
  PubMedGoogle Scholar
• 25 Dinan T G. A rational approach to the non-responding depressed patient.  Int Clin Psychopharmacol. 1993a;  8 221-223
  PubMedGoogle Scholar
• 26 Dinan T G. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study.  Acta Psychiatr Scand. 1993b;  88 300-301
  PubMedGoogle Scholar
• 27 Dinan T G, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, Thakore J, Berti C. Dexamethasone augmentation in treatment-resistant depression.  Acta Psychiatr Scand. 1997;  95 58-61
  PubMedGoogle Scholar
• 28 Ebert D, Jaspert A, Murata H, Kaschka W P. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients.  Psychopharmacology. 1995;  118 223-225
  PubMedGoogle Scholar
• 29 Edwards J G, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors (review).  Drugs. 1999;  57 507-533
  CrossrefPubMedGoogle Scholar
• 30 Egberts A CG, Lenderink A W, De Koning F HP, Leufkens H GM. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment.  J Clin Psychopharmacol. 1997;  17 149-155
  CrossrefPubMedGoogle Scholar
• 31 Evans M, Marwick P. Fluvoxamine and lithium: an unusual interaction.  Br J Psychiatry. 1990;  156 286
  PubMedGoogle Scholar
• 32 Fava M, Rosenbaum J F, Cohen A, Reiter S, McCarthy M, Steingard R, Clancy K. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine.  J Affect Disord. 1992;  25 229-234
  CrossrefPubMedGoogle Scholar
• 33 Fava M, Rosenbaum J F, McGrath P J, Stewart J W, Amsterdam J D, Quitkin F M. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.  Am J Psychiatry. 1994;  151 1372-1374
  PubMedGoogle Scholar
• 34 Finley P R, Warner M D, Peabody C A. Clinical relevance of drug interactions with lithium.  Clin Pharmacokinet. 1995;  29 172-191
  CrossrefPubMedGoogle Scholar
• 35 Flint A J, Rifat S L. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression.  J Clin Psychopharmacol. 1994;  14 353-356
  PubMedGoogle Scholar
• 36 Fontaine R, Ontiveros A, Elie R, Vézina M. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression.  Biol Psychiatry. 1991;  29 946-948
  CrossrefPubMedGoogle Scholar
• 37 Freeman M P, Stoll A L. Mood stabilizer combinations: a review of safety and efficacy.  Am J Psychiatry. 1998;  155 12-21
  PubMedGoogle Scholar
• 38 Gallinat J, Boetsch T, Padberg F, Hampel H, Herrman W M, Hegerl U. Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature.  Pharmacopsychiat. 2000;  33 169-173
  PubMedGoogle Scholar
• 39 Grohman R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI.  Pharmacopsychiat. 1999;  32 21-28
  PubMedGoogle Scholar
• 40 Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician.  Am J Psychiatry. 1991;  148 695-704
  PubMedGoogle Scholar
• 41 Hadley A, Cason M P. Mania resulting from lithium-fluoxetine combination.  Am J Psychiatry. 1989;  146 1637-1638
  PubMedGoogle Scholar
• 42 Hardy B G, Shulman K I, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression.  J Clin Psychopharmacol. 1997;  17 22-26
  CrossrefPubMedGoogle Scholar
• 43 Hawley C J, Roberts A G, Baldwin D S. Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions.  Int Clin Psychopharmacol. 1994a;  9 31-33
  PubMedGoogle Scholar
• 44 Hawley C J, Roberts A G, Walker M H. Tolerability of combined treatment with lithium and paroxetine: 19 cases treated under open conditions.  J Psychopharmacol. 1994b;  8 266-267
  PubMedGoogle Scholar
• 45 Hawley C J, Loughlin P J, Quick S J, Gale T M, Sivakumaran T, Hayes J, McPhee S. for the Hertfordshire Neuroscience Research Group . Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence.  Int Clin Psychopharmacol. 2000;  15 197-206
  PubMedGoogle Scholar
• 46 Heit S, Nemeroff C B. Lithium augmentation of antidepressants in treatment-refractory depression.  J Clin Psychiatry. 1998;  59 28-33
  PubMedGoogle Scholar
• 47 Hilton S E, Maradit H, Möller H J. Serotonin syndrome and drug combinations: focus on MAOI and RIMA.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 113-119
  PubMedGoogle Scholar
• 48 Hopwood S E, Bogle S, Wildgust H J. The combination of fluoxetine and lithium in clinical practice.  Int Clin Psychopharmacol. 1993;  8 325-327
  PubMedGoogle Scholar
• 49 Joffe R T. Refractory depresion: treatment strategies, with particular reference to the thyroid axis.  J Psychiatry Neurosci. 1997;  22 327-331
  PubMedGoogle Scholar
• 50 Joffe R T. The use of thyroid supplements to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 26-29
  PubMedGoogle Scholar
• 51 Kallner G, Lindelius R, Petterson U, Stockman O, Tham A. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it.  Pharmacopsychiat. 2000;  33 8-13
  PubMedGoogle Scholar
• 52 Katona C LE. Refractory depression: a review with particular reference to the use of lithium augmentation.  Eur Neuropsychopharmacol. 1995;  suppl 109-113
  PubMedGoogle Scholar
• 53 Katona C LE, Abou-Saleh M T, Harrison D A, Nairac B A, Edwards D RL, Lock T, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.  Br J Psychiatry. 1995;  166 80-86
  CrossrefPubMedGoogle Scholar
• 54 Kelsey J E. Switching drug class after initial SSRI failure.  J CLin Psychiatry. 1997;  583 26-327
  PubMedGoogle Scholar
• 55 Kojima H, Terao T, Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment.  Am J Psychiatry. 1993;  150 1897
  PubMedGoogle Scholar
• 56 Kupfer D J. Long-term treatment of depression.  J Clin Psychiatry. 1991;  52 (Suppl. 5) 28-34
  PubMedGoogle Scholar
• 57 Lenox R H, McNamara R K, Papke R L, Manji H K. Neurobiology of lithium: an update.  J Clin Psychiatry. 1998;  59 37-47
  PubMedGoogle Scholar
• 58 Leonard B E. Pharmacological and biochemical aspects of therapy-resistant depression.  Int Clin Psychopharmacol. 1991;  6 13-29
  PubMedGoogle Scholar
• 59 McDougle C J, Price L H, Goodman W K, Charney D S, Heninger G R. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.  J Clin Psychopharmacol. 1991;  11 175-184
  PubMedGoogle Scholar
• 60 Mekler G, Woggon B. A case of serotonin syndrome caused by venlafaxine and lithium.  Pharmacopsychiat. 1997;  30 272-273
  PubMedGoogle Scholar
• 61 Montgomery S A. Efficacy in long-term treatment of depression.  J Clin Psychiatry. 1996;  57 24-30
  PubMedGoogle Scholar
• 62 Moreno F A, Gelenberg A J, Bachar K, Delgado P L. Pindolol augmentation of treatment-resistant depressed patients.  J Clin Psychiatry. 1997;  58 437-439
  PubMedGoogle Scholar
• 63 Muly E C, Mcdonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium.  Am J Psychiatry. 1993;  150 1565
  PubMedGoogle Scholar
• 64 Nelson J C, Price L H. Lithium or desipramine augmentation of fluoxetine treatment.  Am J Psychiatry. 1995;  152 1538-1539
  PubMedGoogle Scholar
• 65 Nelson J C. Augmentation strategies with serotonergic-noradrenergic combinations.  J Clin Psychiatry. 1998;  59 65-68
  PubMedGoogle Scholar
• 66 Nierenberg A A, Amsterdam J D. Treatment-resistant depression: definition and treatment approaches.  J Clin Psychiatry. 1990;  6 39-47
  PubMedGoogle Scholar
• 67 Nisijima K, Shimizu M, Abe T, Ishiguro T. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium.  Int Clin Psychopharmacol. 1996;  11 289-290
  PubMedGoogle Scholar
• 68 Noveske F G, Hahn K R, Flynn R J. Possible toxicity of combined fluoxetine and lithium.  Am J Psychiatry. 1989;  146 1515
  PubMedGoogle Scholar
• 69 O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.  J Clin Psychopharmacol. 1998;  18 89-91
  CrossrefPubMedGoogle Scholar
• 70 Okamoto Y, Motohashi N, Hayakawa H, Muraoka M, Yamawaki S. Addition of lithium to chronic antidepressant treatment potentiates presynaptic serotonergic function without changes in serotonergic receptors in the rat cerebral cortex.  Pharmacopsychiat. 1996;  33 17-20
  PubMedGoogle Scholar
• 71 Öhman A, Spigset O. Serotonin syndrome induced by fluvoxamine-lithium interaction.  Pharmacopsychiat. 1993;  26 263-264
  PubMedGoogle Scholar
• 72 Pope H G, McElroy S L, Noxon R A. Possible synergism between fluoxetine and lithium in refractory depression.  Am J Psychiatry. 1988;  145 1292-1294
  PubMedGoogle Scholar
• 73 Price L H, Charney D S, Heninger G R. Variability of response to lithium augmentation in refractory depression.  Am J Psychiatry. 1986;  143 1387-1392
  PubMedGoogle Scholar
• 74 Reynolds C F, Frank E, Perel J M, Mazumdar S, Dew M A, Begley A, Kupfer D J, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression.  Am J Psychiatry. 1996;  153 1418-1422
  PubMedGoogle Scholar
• 75 Rihmer Z, Kiss G H, Kecskes I, Pestality P, György S. SSRI supplementation of antimanic medication in dysphoric mania.  Pharmacopsychiat. 1998;  31 30-31
  PubMedGoogle Scholar
• 76 Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 32-39
  PubMedGoogle Scholar
• 77 Rush A J, Thase M E. Strategies and tactics in the treatment of chronic depression.  J Clin Psychiatry. 1997;  58 14-22
  PubMedGoogle Scholar
• 78 Sacristan J A, Iglesias C, Arellano F, Lequercia J. Absence seizures induced by lithium: possible interaction with fluoxetine.  Am J Psychiatry. 1991;  148 146-147
  PubMedGoogle Scholar
• 79 Salama A A, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate.  Am J Psychiatry. 1989;  146 278
  PubMedGoogle Scholar
• 80 Schmauss M, Erfurth A. Kombinationstherapien bei Therapieresistenz auf Antidepressiva - eine Übersicht.  Fortschr Neurol Psychiatr. 1996;  64 390-402
  PubMedGoogle Scholar
• 81 Schou M. Has the time come to abandon prophylactic lithium treatment? A review for clinicians.  Pharmacopsychiat. 1998;  31 210-215
  PubMedGoogle Scholar
• 82 Schöpf J. Treatment of depression resistant to tricyclic antidepressants, related drugs or MAO-inhibits by lithium addition: review of the literature.  Pharmacopsychiat. 1989;  22 174-182
  PubMedGoogle Scholar
• 83 Schöpf J, Baumann P, Lemarchand T, Rey J M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study.  Pharmacopsychiat. 1989;  22 183-187
  PubMedGoogle Scholar
• 84 Seth R, Jennings A L, Bindman J, Phillips J, Bergmann K. Combination tratement with noradrenaline and serotonin reuptake inhibitors in resistant depression.  Br J Psychiatry. 1992;  161 562-565
  PubMedGoogle Scholar
• 85 Slama M, Masmoudi K, Blanchard N, Andréjak M. A possible case of lithium intoxication mimicking Creutzfeld-Jakob syndrome.  Pharmacopsychiat. 2000;  33 145-146
  PubMedGoogle Scholar
• 86 Sluzewska A, Sobieska M, Rybanowski J K. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression.  Biol Psychiatry. 1997;  35 123-127
  PubMedGoogle Scholar
• 87 Sobanski T, Bagli M, Laux G, Rao M L. Serotonin syndrome after lithium add-on medication to paroxetine.  Pharmacopsychiat. 1997;  30 106-107
  PubMedGoogle Scholar
• 88 Sokolov S TH, Joffe R T. Practical guidelines for combination drug therapy of treatment-resistant depression.  CNS Drugs. 1995;  4 341-350
  PubMedGoogle Scholar
• 89 Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation - pilot study.  J Aff Disord. 1998;  49 235-239
  PubMedGoogle Scholar
• 90 Sprenger D. Buspirone augmentation of a selective serotonin reuptake inhibitor: efficacy in two depressed patients with comorbid anxiety and type I alcohol dependence.  J Clin Psychopharmacol. 1997;  17 425-426
  CrossrefPubMedGoogle Scholar
• 91 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713
  PubMedGoogle Scholar
• 92 Sussman N, Joffe R T. Augmentation of antidepressant medication.  J Clin Psychiatry. 1998;  59 3-4
  PubMedGoogle Scholar
• 93 Terao T. Rapid synergistic effects of lithium and antidepressants.  Psychopharmacology. 1995;  122 206-207
  PubMedGoogle Scholar
• 94 Thase M E, Blomgren S L, Birkett M A, Apter J T, Tepner R G. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.  J Clin Psychiatry. 1997;  58 16-21
  PubMedGoogle Scholar
• 95 Thase M E, Howland R H, Friedman E S. Treating antidepressant nonresponders with augmentation strategies: an overview.  J Clin Psychiatry. 1998;  59 5-12
  PubMedGoogle Scholar
• 96 Uchitomi Y, Yamawaki S. Chronic lithium traetment enhances the postsynaptic 5-HT_1A receptor mediated 5-HT behavioral syndrome induced by 8-OH-DPAT in rats via catecholaminergic systems.  Psychopharmacology. 1993;  112 74-79
  PubMedGoogle Scholar
• 97 Uehlinger C, Nil R, Amey M, Baumann P, Dufour H. Citalopram-lithium combination treatment of elderly depressed patients: a pilot study.  Int J Ger Psychiatry. 1995;  10 281-287
  PubMedGoogle Scholar

1 This contribution was part of an oral presentation at the ECNP meeting in Vienna, 1997 (Baumann, P. Advantages and disadvantages of lithium augmentation. Eur. Neuropsychopharmacol. 7 (suppl. 2): the S82, 1997. [Abstract])

Daniele ZullinoMD 

Unité de Biochimie et
Psychopharmacologie Clinique
Département Universitaire de
Psychiatrie Adulte

1008 Prilly-Lausanne
Switzerland